Crinetics Pharmaceuticals (CRNX)
(Delayed Data from NSDQ)
$42.19 USD
-2.68 (-5.97%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $42.18 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.19 USD
-2.68 (-5.97%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $42.18 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Wall Street Analysts Believe Crinetics Pharmaceuticals, Inc. (CRNX) Could Rally 45%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Crinetics Pharmaceuticals, Inc. (CRNX) points to a 45.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Should You Buy Crinetics Pharmaceuticals (CRNX) Ahead of Earnings?
by Zacks Equity Research
Crinetics Pharmaceuticals (CRNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Crinetics Pharmaceuticals, Inc. (CRNX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Crinetics Pharmaceuticals, Inc. (CRNX).
Is Crinetics Pharmaceuticals (CRNX) Stock a Solid Choice Right Now?
by Zacks Equity Research
Crinetics Pharmaceuticals (CRNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Crinetics Pharmaceuticals, Inc. (CRNX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Crinetics Pharmaceuticals, Inc. (CRNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -11.11% and 51.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Crinetics Pharmaceuticals (CRNX) a Strong Sell?
by Zacks Equity Research
Crinetics Pharmaceuticals (CRNX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -13.33% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?